Pacific Edge has made solid progress in recent months toward the start of broad commercialisation of its bladder cancer diagnostics tests in the US, with a third test becoming available there in mid-2016. In February, the Veterans Administration (VA) handed down a positive decision on its Cxbladder testing technology just as large-scale User Programmes in the US near completion. The Kaiser Permanente (KP) pilot is expected to be completed by the end of 2016 and could result in significant sales traction.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs